ArticleJAMA network open2020

Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors.

David Bomze et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.